HC Wainwright & Co. Reiterates Buy on MiNK Therapeutics, Maintains $9 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating for MiNK Therapeutics (NASDAQ:INKT) and maintained a price target of $9, indicating continued confidence in the company's potential.
October 09, 2024 | 10:45 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating for MiNK Therapeutics and maintained a $9 price target, suggesting confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $9 price target by HC Wainwright & Co. indicates a positive outlook for MiNK Therapeutics. This can lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100